Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
1.22
-0.01 (-1.22%)
Market open: Aug 12, 2026, 11:46 AM EDT
1.21
-0.02 (-1.46%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial. It has license agreement with Meiji Seika Pharma Co., Ltd. to develop, manufacture, and commercialize tebipenem pivoxil and tebipenem HBr; and Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries. Spero Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
| Name | Position |
|---|---|
| Dr. Debra Jeske Zack M.D., Ph.D. | Chief Medical Officer |
| Mr. John Raymond | Senior Vice President of Finance & Business Operations |
| Mr. Timothy Keutzer | Chief Operating Officer |
| Ms. Esther P. Rajavelu | CEO, President, CFO, Chief Business Officer, Treasurer & Director |
| Ms. Sheila Finan | Senior VP & Controller |
| Date | Type | Document |
|---|---|---|
| 2026-07-14 | 8-K | d320658d8k.htm |
| 2026-06-25 | 8-K | d86736d8k.htm |
| 2026-06-23 | S-8 | d155753ds8.htm |
| 2026-06-22 | 8-K | d51395d8k.htm |
| 2026-05-13 | 8-K | d147628d8k.htm |
| 2026-05-13 | 10-Q | spro-20260331.htm |
| 2026-04-27 | DEFA14A | d120525ddefa14a.htm |
| 2026-04-27 | DEF 14A | d45106ddef14a.htm |
| 2026-04-27 | ARS | d22424dars.pdf |
| 2026-04-13 | PRE 14A | d45106dpre14a.htm |